JW (Cayman) Therapeutics Co Ltd
HKEX:2126
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
CN |
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
771.2m HKD | -1.1 | ||
US |
Abbvie Inc
NYSE:ABBV
|
284.3B USD | 9 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
166B USD | 11 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 11.1 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.4B USD | 8.7 | ||
AU |
CSL Ltd
ASX:CSL
|
133.8B AUD | 13.4 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.9B USD | 3.7 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
47.9B USD | 34.5 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 24.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.1B USD | 5.2 | ||
KR |
Celltrion Inc
KRX:068270
|
39.3T KRW | 38.3 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.